CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced results from a Phase 1 study of romidepsin in combination with gemcitabine in patients with solid tumors. The results from the Phase 1 study showed that the combination was generally well tolerated and indicated that further investigation of romidepsin as a potential treatment in multiple cancer indications may be warranted. The results were presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1, 2008. Romidepsin is a novel, cyclic peptide, pan-HDAC inhibitor.
